References
- Alexopoulos, G. S., Jeste, D. V., Chung, H., Carpenter, D., Ross, R., & Docherty, J. P. (2005). The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: Methods, commentary, and summary. Postgrad Med, Spec No, 6–22.
- Antipsychotic Medication Measure Methodology. (2018). Retrieved from https://www.cdph.ca.gov/Programs/CHCQ/LCP/CDPH%20Document%20Library/SNF_QASP_AntipsychoticMedicationMeasureMethodology_May%202017.pdf
- APCD. (2020). Retrieved from http://www.vhi.org/apcd.
- Briesacher, B. A., Tjia, J., Field, T., Peterson, D., & Gurwitz, J. H. (2013). Antipsychotic use among nursing home residents. JAMA, 309(5), 440–442. doi:10.1001/jama.2012.211266
- Busch, S. H., Cohen, M. S., & Konetzka, R. T. (2019). Assessing the relative contribution of resident versus facility characteristics associated with antipsychotic medication receipt among nursing facility residents. Medical Care, 57(10), 822–829. doi:10.1097/MLR.0000000000001183
- Castle, N. G., Hanlon, J. T., & Handler, S. M. (2009). Results of a longitudinal analysis of national data to examine relationships between organizational and market characteristics and changes in antipsychotic prescribing in US nursing homes from 1996 through 2006. The American Journal of Geriatric Pharmacotherapy, 7(3), 143–150. doi:10.1016/j.amjopharm.2009.05.001
- Chen, Y., Briesacher, B. A., Field, T. S., Tjia, J., Lau, D. T., & Gurwitz, J. H. (2010). Unexplained variation across US nursing homes in antipsychotic prescribing rates. Archives of Internal Medicine, 170(1), 89–95. doi:10.1001/archinternmed.2009.469
- CMS Announces National Partnership. (2012). Retrieved from https://www.cms.gov/Newsroom/MediaReleaseDatabase/Press-Releases/2012-Press-Releases-Items/2012-05-30.html
- Enhanced Oversight and Enforcement of Non-Improving Late Adopters. (2019). Retrieved from https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Downloads/QSO-19-07-Enhanced-Oversight-and-Enforcement-of-Non-Improving-Late-Adopters.pdf
- Fashaw, S., Chisholm, L., Mor, V., Meyers, D. J., Liu, X., Gammonley, D., & Thomas, K. (2020). Inappropriate antipsychotic use: The impact of nursing home socioeconomic and racial composition. Journal of the American Geriatrics Society, 68(3), 630–636. doi:10.1111/jgs.16316
- Health Disparities Data. (2020). Retrieved from https://www.healthypeople.gov/2020/data-search/Search-the-Data?topic-area=3499
- Hughes, C. M., Lapane, K. L., & Mor, V. (2000). Influence of facility characteristics on use of antipsychotic medications in nursing homes. Medical Care, 38(12), 1164–1173. doi:10.1097/00005650-200012000-00003
- Interim report on the CMS National Partnership. (2016). Retrieved from https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Downloads/Survey-and-Cert-Letter-16-28.pdf
- Kerns, J. W., Winter, J. D., Winter, K. M., Boyd, T., & Etz, R. S. (2018). Primary care physician perspectives about antipsychotics and other medications for symptoms of dementia. Journal of the American Board of Family Medicine: JABFM, 31(1), 9–21. doi:10.3122/jabfm.2018.01.170230
- Kerns, J. W., Winter, J. D., Winter, K. M., Kerns, C. C., & Etz, R. S. (2018). Caregiver perspectives about using antipsychotics and other medications for symptoms of dementia. Gerontologist, 58(2), e35–e45. doi:10.1093/geront/gnx042
- Lackner, T. E., Cloyd, J. C., Thomas, L. W., & Leppik, I. E. (1998). Antiepileptic drug use in nursing home residents: Effect of age, gender, and comedication on patterns of use. Epilepsia, 39(10), 1083–1087. doi:10.1111/j.1528-1157.1998.tb01294.x
- Late Adopter Data Report. (2021). Retrieved from https://www.cms.gov/files/document/late-adopter-data-report-2021q2-updated-01142022.pdf
- Mays, V. M., Cochran, S. D., & Barnes, N. W. (2007). Race, race-based discrimination, and health outcomes among African Americans. Annu Rev Psychol, 58(1), 201–225. doi:10.1146/annurev.psych.57.102904.190212
- National Healthcare Quality and Disparities Report. (2018). Retrieved from https://www.ahrq.gov/research/findings/nhqrdr/nhqdr18/index.html
- Provider Information. (2022). Retrieved from https://data.cms.gov/provider-data/dataset/4pq5-n9py
- Social Determinants of Health: CDC. (2022). Retrieved from https://www.cdc.gov/socialdeterminants/index.htm
- Stevenson, D. G., Decker, S. L., Dwyer, L. L., Huskamp, H. A., Grabowski, D. C., Metzger, E. D., & Mitchell, S. L. (2010). Antipsychotic and benzodiazepine use among nursing home residents: Findings from the 2004 national nursing home survey. The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry, 18(12), 1078–1092. doi:10.1097/JGP.0b013e3181d6c0c6
- Virginia HOI: Health Matters, Place Matters. (2022). Retrieved from https://apps.vdh.virginia.gov/omhhe/hoi/
- Winter, J. D., Kerns, J. W., & Sabo, R. (2022). The impact of social and community factors on inappropriate long-stay antipsychotic use in Virginia nursing homes. Geropsych.
- Winter, J. D., Kerns, J. W., Winter, K. M., Richards, A., & Sabo, R. T. (2021). Unreported antipsychotic use increasing in nursing homes: The impact of quality-measure exclusions on the percentage of long-stay residents who got an antipsychotic medication quality-measure. The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry, 29(7), 704–708. doi:10.1016/j.jagp.2020.11.008
- Winter, J. D., Kerns, J. W., Winter, K. M., & Sabo, R. T. (2019). Increased reporting of exclusionary diagnoses inflate apparent reductions in long-stay antipsychotic prescribing. Clinical Gerontologist, 42(3), 297–301. doi:10.1080/07317115.2017.1395378